| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Diseases | 9 | 2011 | 53 | 1.610 |
Why?
|
| Hypertension | 13 | 2022 | 500 | 1.510 |
Why?
|
| Blood Pressure | 8 | 2021 | 298 | 1.350 |
Why?
|
| Kidney Failure, Chronic | 10 | 2012 | 147 | 1.070 |
Why?
|
| Humans | 72 | 2024 | 17611 | 0.920 |
Why?
|
| Medication Adherence | 6 | 2022 | 244 | 0.910 |
Why?
|
| Antihypertensive Agents | 4 | 2021 | 161 | 0.900 |
Why?
|
| Transgender Persons | 5 | 2023 | 38 | 0.890 |
Why?
|
| Male | 57 | 2024 | 10008 | 0.840 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2016 | 171 | 0.830 |
Why?
|
| Middle Aged | 48 | 2022 | 7911 | 0.810 |
Why?
|
| Albuminuria | 7 | 2011 | 38 | 0.790 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2015 | 179 | 0.750 |
Why?
|
| Coronary Disease | 6 | 2016 | 181 | 0.750 |
Why?
|
| Female | 55 | 2024 | 12608 | 0.720 |
Why?
|
| Societies, Medical | 1 | 2020 | 74 | 0.710 |
Why?
|
| Aged | 34 | 2021 | 6095 | 0.640 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 531 | 0.600 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2013 | 748 | 0.600 |
Why?
|
| Cardiology | 1 | 2017 | 30 | 0.580 |
Why?
|
| American Heart Association | 1 | 2017 | 49 | 0.580 |
Why?
|
| United States | 30 | 2017 | 3956 | 0.570 |
Why?
|
| Adult | 33 | 2022 | 7598 | 0.560 |
Why?
|
| Creatinine | 5 | 2010 | 65 | 0.560 |
Why?
|
| Patient Compliance | 2 | 2016 | 298 | 0.550 |
Why?
|
| Smoking | 5 | 2014 | 483 | 0.540 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 375 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 318 | 0.530 |
Why?
|
| Glomerular Filtration Rate | 8 | 2012 | 153 | 0.510 |
Why?
|
| Arabs | 1 | 2014 | 2 | 0.490 |
Why?
|
| Tobacco Products | 1 | 2014 | 17 | 0.480 |
Why?
|
| Diabetic Nephropathies | 2 | 2011 | 26 | 0.460 |
Why?
|
| Heart Failure | 5 | 2022 | 396 | 0.460 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 2024 | 6 | 0.450 |
Why?
|
| Risk Factors | 24 | 2020 | 3325 | 0.430 |
Why?
|
| Atherosclerosis | 2 | 2010 | 51 | 0.410 |
Why?
|
| Cystatin C | 2 | 2009 | 15 | 0.410 |
Why?
|
| Cardiovascular Diseases | 8 | 2016 | 598 | 0.410 |
Why?
|
| Health Behavior | 1 | 2014 | 359 | 0.400 |
Why?
|
| Stroke | 6 | 2020 | 311 | 0.400 |
Why?
|
| Silicon Dioxide | 1 | 2011 | 3 | 0.400 |
Why?
|
| Nutrition Surveys | 11 | 2009 | 61 | 0.400 |
Why?
|
| Cohort Studies | 17 | 2022 | 2570 | 0.390 |
Why?
|
| Occupational Diseases | 1 | 2011 | 41 | 0.390 |
Why?
|
| Occupational Exposure | 1 | 2011 | 67 | 0.380 |
Why?
|
| Retrospective Studies | 13 | 2024 | 2447 | 0.370 |
Why?
|
| Hypotension, Orthostatic | 1 | 2010 | 1 | 0.370 |
Why?
|
| Body Mass Index | 5 | 2024 | 958 | 0.360 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 1900 | 0.360 |
Why?
|
| Electronic Health Records | 5 | 2020 | 681 | 0.310 |
Why?
|
| Hospitalization | 4 | 2020 | 797 | 0.300 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2007 | 4 | 0.300 |
Why?
|
| Models, Statistical | 1 | 2009 | 177 | 0.300 |
Why?
|
| Risk Assessment | 8 | 2020 | 1097 | 0.300 |
Why?
|
| Anticholesteremic Agents | 2 | 2014 | 14 | 0.290 |
Why?
|
| African Continental Ancestry Group | 2 | 2010 | 162 | 0.290 |
Why?
|
| Cognition | 1 | 2007 | 81 | 0.280 |
Why?
|
| Follow-Up Studies | 14 | 2022 | 1210 | 0.270 |
Why?
|
| African Americans | 5 | 2021 | 472 | 0.260 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 24 | 0.250 |
Why?
|
| Food Contamination | 1 | 2005 | 3 | 0.250 |
Why?
|
| Fishes | 1 | 2005 | 10 | 0.250 |
Why?
|
| Mercury | 1 | 2005 | 4 | 0.250 |
Why?
|
| Chronic Disease | 6 | 2011 | 428 | 0.240 |
Why?
|
| Transsexualism | 2 | 2023 | 10 | 0.240 |
Why?
|
| Reminder Systems | 2 | 2016 | 80 | 0.240 |
Why?
|
| Kidney | 2 | 2007 | 52 | 0.240 |
Why?
|
| Body Height | 1 | 2024 | 62 | 0.240 |
Why?
|
| Cross-Sectional Studies | 9 | 2020 | 1322 | 0.230 |
Why?
|
| Kidney Calculi | 1 | 2004 | 6 | 0.230 |
Why?
|
| Indians, North American | 3 | 2009 | 49 | 0.230 |
Why?
|
| Renal Insufficiency | 1 | 2004 | 13 | 0.230 |
Why?
|
| Myocardial Infarction | 2 | 2016 | 238 | 0.230 |
Why?
|
| Young Adult | 7 | 2024 | 2427 | 0.220 |
Why?
|
| Adolescent | 8 | 2024 | 3651 | 0.220 |
Why?
|
| Incidence | 10 | 2020 | 1255 | 0.220 |
Why?
|
| Life Style | 2 | 2010 | 332 | 0.210 |
Why?
|
| Disease Progression | 3 | 2013 | 264 | 0.210 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2022 | 3 | 0.210 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 27 | 0.210 |
Why?
|
| Self-Injurious Behavior | 1 | 2023 | 44 | 0.210 |
Why?
|
| Coronary Artery Disease | 2 | 2014 | 134 | 0.200 |
Why?
|
| Social Values | 1 | 2021 | 14 | 0.200 |
Why?
|
| Medicare | 3 | 2014 | 202 | 0.200 |
Why?
|
| Epidemiologic Studies | 2 | 2020 | 29 | 0.190 |
Why?
|
| Racism | 1 | 2021 | 19 | 0.190 |
Why?
|
| Databases, Factual | 4 | 2016 | 309 | 0.190 |
Why?
|
| Gender Identity | 4 | 2023 | 36 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2020 | 1259 | 0.190 |
Why?
|
| European Continental Ancestry Group | 5 | 2020 | 529 | 0.190 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 10 | 0.190 |
Why?
|
| Attitude to Health | 1 | 2021 | 164 | 0.180 |
Why?
|
| Health Care Costs | 2 | 2013 | 228 | 0.180 |
Why?
|
| Health Status Indicators | 1 | 2020 | 64 | 0.180 |
Why?
|
| Office Visits | 1 | 2021 | 80 | 0.180 |
Why?
|
| Primary Prevention | 1 | 2020 | 73 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2021 | 218 | 0.170 |
Why?
|
| Child | 6 | 2024 | 2474 | 0.170 |
Why?
|
| Prevalence | 6 | 2023 | 884 | 0.170 |
Why?
|
| Population Surveillance | 3 | 2012 | 263 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 88 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2023 | 280 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2011 | 1115 | 0.170 |
Why?
|
| Glycated Hemoglobin A | 1 | 2021 | 216 | 0.170 |
Why?
|
| Cholesterol, LDL | 2 | 2016 | 119 | 0.170 |
Why?
|
| Prospective Studies | 8 | 2020 | 1267 | 0.170 |
Why?
|
| Suicide, Attempted | 1 | 2020 | 96 | 0.170 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 434 | 0.160 |
Why?
|
| Genetic Linkage | 2 | 2009 | 7 | 0.160 |
Why?
|
| Diabetes Mellitus | 4 | 2012 | 487 | 0.160 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 120 | 0.160 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 170 | 0.160 |
Why?
|
| Sex Factors | 5 | 2020 | 643 | 0.160 |
Why?
|
| North Carolina | 3 | 2010 | 33 | 0.160 |
Why?
|
| Proportional Hazards Models | 9 | 2020 | 709 | 0.160 |
Why?
|
| Medical Records | 1 | 2018 | 100 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 129 | 0.140 |
Why?
|
| Risk | 4 | 2010 | 516 | 0.140 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 454 | 0.140 |
Why?
|
| Medical Record Linkage | 2 | 2016 | 38 | 0.130 |
Why?
|
| Social Class | 2 | 2008 | 120 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 39 | 0.130 |
Why?
|
| Drug Costs | 1 | 2016 | 34 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 98 | 0.130 |
Why?
|
| Age Factors | 5 | 2020 | 917 | 0.130 |
Why?
|
| HIV Infections | 1 | 2022 | 694 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2016 | 66 | 0.130 |
Why?
|
| Hemoglobins | 2 | 2012 | 39 | 0.120 |
Why?
|
| Middle East | 1 | 2014 | 2 | 0.120 |
Why?
|
| Health Priorities | 1 | 2014 | 26 | 0.120 |
Why?
|
| Smoking Prevention | 1 | 2014 | 54 | 0.120 |
Why?
|
| Withholding Treatment | 1 | 2014 | 26 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 211 | 0.120 |
Why?
|
| Outcome and Process Assessment (Health Care) | 2 | 2012 | 102 | 0.120 |
Why?
|
| Coronary Angiography | 1 | 2013 | 21 | 0.110 |
Why?
|
| Fee-for-Service Plans | 1 | 2013 | 24 | 0.110 |
Why?
|
| Medicare Part C | 1 | 2013 | 19 | 0.110 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 22 | 0.110 |
Why?
|
| Coronary Artery Bypass | 1 | 2013 | 26 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2013 | 92 | 0.110 |
Why?
|
| Data Collection | 2 | 2012 | 256 | 0.110 |
Why?
|
| C-Reactive Protein | 3 | 2009 | 58 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2014 | 193 | 0.110 |
Why?
|
| Biomarkers | 3 | 2016 | 301 | 0.110 |
Why?
|
| Research Report | 1 | 2012 | 22 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2016 | 86 | 0.100 |
Why?
|
| Benchmarking | 1 | 2012 | 46 | 0.100 |
Why?
|
| Anemia | 1 | 2012 | 32 | 0.100 |
Why?
|
| Quantitative Trait Loci | 2 | 2009 | 36 | 0.100 |
Why?
|
| Proteinuria | 1 | 2012 | 26 | 0.100 |
Why?
|
| Prognosis | 5 | 2014 | 606 | 0.100 |
Why?
|
| Time Factors | 3 | 2020 | 1086 | 0.100 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 72 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2012 | 254 | 0.100 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 79 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 181 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2012 | 189 | 0.090 |
Why?
|
| Perception | 1 | 2010 | 58 | 0.090 |
Why?
|
| Rural Population | 1 | 2010 | 51 | 0.090 |
Why?
|
| Diet | 2 | 2002 | 365 | 0.080 |
Why?
|
| American Native Continental Ancestry Group | 1 | 2009 | 2 | 0.080 |
Why?
|
| Documentation | 1 | 2009 | 42 | 0.080 |
Why?
|
| Kidney Function Tests | 1 | 2009 | 22 | 0.080 |
Why?
|
| Quality of Life | 2 | 2020 | 507 | 0.080 |
Why?
|
| Obesity | 4 | 2009 | 837 | 0.080 |
Why?
|
| Carbonated Beverages | 1 | 2008 | 14 | 0.080 |
Why?
|
| Social Conditions | 1 | 2008 | 2 | 0.080 |
Why?
|
| Logistic Models | 3 | 2008 | 926 | 0.080 |
Why?
|
| Residence Characteristics | 2 | 2008 | 248 | 0.080 |
Why?
|
| Socioeconomic Factors | 4 | 2014 | 630 | 0.070 |
Why?
|
| Health Promotion | 1 | 2010 | 280 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 80 | 0.070 |
Why?
|
| Algorithms | 1 | 2008 | 233 | 0.070 |
Why?
|
| Models, Biological | 1 | 2007 | 30 | 0.070 |
Why?
|
| Medicaid | 1 | 2008 | 186 | 0.070 |
Why?
|
| Health Status Disparities | 2 | 2021 | 146 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2008 | 710 | 0.060 |
Why?
|
| Managed Care Programs | 3 | 2012 | 325 | 0.060 |
Why?
|
| Anthropometry | 1 | 2024 | 66 | 0.060 |
Why?
|
| Infant | 2 | 2024 | 1171 | 0.060 |
Why?
|
| Animals | 1 | 2005 | 259 | 0.060 |
Why?
|
| Health Status | 2 | 2022 | 298 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2024 | 1409 | 0.060 |
Why?
|
| Body Weight | 1 | 2024 | 219 | 0.050 |
Why?
|
| Lead Poisoning | 1 | 2003 | 3 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 2003 | 4 | 0.050 |
Why?
|
| Sexual Development | 1 | 2022 | 4 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2002 | 9 | 0.050 |
Why?
|
| Fruit | 1 | 2002 | 79 | 0.050 |
Why?
|
| Folic Acid | 1 | 2002 | 32 | 0.050 |
Why?
|
| Vegetables | 1 | 2002 | 87 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 178 | 0.050 |
Why?
|
| Writing | 1 | 2021 | 11 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 44 | 0.050 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 47 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2001 | 1 | 0.050 |
Why?
|
| Mental Health | 1 | 2023 | 165 | 0.050 |
Why?
|
| Mass Screening | 1 | 2007 | 661 | 0.050 |
Why?
|
| Colorado | 1 | 2021 | 163 | 0.050 |
Why?
|
| Illinois | 1 | 2020 | 8 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 16 | 0.050 |
Why?
|
| Embolism | 1 | 2020 | 6 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2011 | 237 | 0.050 |
Why?
|
| Safety | 1 | 2020 | 41 | 0.050 |
Why?
|
| Demography | 1 | 2020 | 101 | 0.050 |
Why?
|
| Self Report | 1 | 2022 | 251 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 368 | 0.040 |
Why?
|
| Sex Distribution | 3 | 2009 | 190 | 0.040 |
Why?
|
| Lipoproteins | 1 | 1999 | 14 | 0.040 |
Why?
|
| Sodium, Dietary | 1 | 1999 | 10 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 351 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 201 | 0.040 |
Why?
|
| Anxiety | 1 | 2020 | 150 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2020 | 100 | 0.040 |
Why?
|
| Mortality | 1 | 1999 | 117 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1999 | 34 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2020 | 404 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 322 | 0.040 |
Why?
|
| Reference Values | 2 | 2009 | 91 | 0.040 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 8 | 0.030 |
Why?
|
| Fibrinogen | 2 | 2009 | 13 | 0.030 |
Why?
|
| Homocysteine | 2 | 2009 | 13 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 15 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 10 | 0.030 |
Why?
|
| Models, Economic | 1 | 2016 | 19 | 0.030 |
Why?
|
| Health Resources | 1 | 2016 | 37 | 0.030 |
Why?
|
| Diabetes Complications | 2 | 2010 | 114 | 0.030 |
Why?
|
| Depression | 1 | 2020 | 502 | 0.030 |
Why?
|
| Cotinine | 2 | 2007 | 7 | 0.030 |
Why?
|
| Nutrition Assessment | 2 | 2007 | 26 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 129 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 250 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 85 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 66 | 0.030 |
Why?
|
| Lipids | 1 | 2014 | 77 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 114 | 0.030 |
Why?
|
| Telephone | 1 | 2014 | 161 | 0.030 |
Why?
|
| Capitation Fee | 1 | 2013 | 12 | 0.030 |
Why?
|
| Geography | 1 | 2013 | 39 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 27 | 0.030 |
Why?
|
| Health Surveys | 2 | 2007 | 260 | 0.030 |
Why?
|
| Health Maintenance Organizations | 1 | 2014 | 417 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2012 | 26 | 0.030 |
Why?
|
| Age of Onset | 1 | 2012 | 79 | 0.030 |
Why?
|
| Morbidity | 1 | 2011 | 59 | 0.020 |
Why?
|
| Oregon | 1 | 2011 | 171 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 135 | 0.020 |
Why?
|
| Decision Making | 1 | 2012 | 183 | 0.020 |
Why?
|
| Energy Intake | 2 | 2002 | 101 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2011 | 305 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 471 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 190 | 0.020 |
Why?
|
| Focus Groups | 1 | 2010 | 147 | 0.020 |
Why?
|
| Georgia | 1 | 2009 | 26 | 0.020 |
Why?
|
| Health Education | 1 | 2010 | 111 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2009 | 1 | 0.020 |
Why?
|
| North Dakota | 1 | 2009 | 1 | 0.020 |
Why?
|
| South Dakota | 1 | 2009 | 1 | 0.020 |
Why?
|
| Oklahoma | 1 | 2009 | 2 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Arizona | 1 | 2009 | 5 | 0.020 |
Why?
|
| Hyperuricemia | 1 | 2009 | 2 | 0.020 |
Why?
|
| Phosphorus | 1 | 2009 | 6 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2009 | 23 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2008 | 19 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2008 | 8 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2008 | 17 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2008 | 32 | 0.020 |
Why?
|
| Family Health | 1 | 2008 | 44 | 0.020 |
Why?
|
| Research | 1 | 2008 | 64 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 91 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2008 | 70 | 0.020 |
Why?
|
| Warfarin | 1 | 2008 | 74 | 0.020 |
Why?
|
| Phenotype | 1 | 2008 | 149 | 0.020 |
Why?
|
| Community Health Services | 1 | 2008 | 83 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2002 | 1309 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 289 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 594 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2008 | 77 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2008 | 133 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2012 | 766 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 304 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2008 | 326 | 0.020 |
Why?
|
| Aging | 1 | 2007 | 161 | 0.020 |
Why?
|
| Hyperhomocysteinemia | 1 | 2003 | 5 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 62 | 0.010 |
Why?
|
| Systole | 1 | 2002 | 22 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 50 | 0.010 |
Why?
|
| Software | 1 | 2002 | 22 | 0.010 |
Why?
|
| Mental Recall | 1 | 2002 | 31 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2002 | 24 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 106 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2002 | 91 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 231 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2001 | 57 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2003 | 671 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 381 | 0.010 |
Why?
|
| Death Certificates | 1 | 2001 | 19 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2001 | 20 | 0.010 |
Why?
|
| Educational Status | 1 | 2001 | 200 | 0.010 |
Why?
|
| Continental Population Groups | 1 | 2002 | 302 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 568 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1999 | 159 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1999 | 215 | 0.010 |
Why?
|
| Cause of Death | 1 | 1999 | 181 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 1999 | 116 | 0.010 |
Why?
|
| Exercise | 1 | 2001 | 489 | 0.010 |
Why?
|